Forte Biosciences Inc FBRX
76.99 USD 0.00 (+0.00%)
At closeAug 26, 2026, 4:00 PM EDT
21.03 -55.96 -72.68%
After hours · Aug 26, 4:00 PM ET
76.96 Day range 77.00
10.30 52-week range 77.20
- YTD
- +182.32%
- 1 year
- +574.76%
- Market cap
- 1.63B
- EPS (ttm)
- -4.65
- Shares out
- 21.23M
- Forward P/E
- -18.89
- YTD return
- +182.32%
- 1-year return
- +574.76%
- Volume
- 1.40M
- Avg volume
- 1.86M
- Open
- 76.97
- Previous close
- 76.99
- Day's range
- 76.96 – 77.00
- 52-week range
- 10.30 – 77.20
- Beta
- 2.65
- Analysts
- Buy
- Price target
- 73.00 (-5.2%)
- Earnings date
- Nov 13, 2026
2Y 0.00 (0.00%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 1.74B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 10.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -41.29M
- Total cash
- 198.46M
- Total debt
- 0
- Return on equity
- -62.28%
- Short % of float
- 7.74%
- 50-day average
- 55.18
- 200-day average
- 33.25
Analyst view
Consensus: buy
Buy
Price target (mean) 73.00 -5.2% downside
Now 76.99
- Target (low)
- 61.00
- Target (mean)
- 73.00
- Target (high)
- 77.00
Ratings (0m) 4 1 buy · 3 hold · 0 sell
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 13, 2026
Expected Nov 13, 2026. Consensus EPS estimate -1.09.
Financials — quick view
FBRX Revenue — quarterly 0
FBRX Net income — quarterly -23.33M
FBRX EPS — quarterly -0.97
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -0.90 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -1.08 | -0.97 | +0.11 | +10.19% |
| May 21, 2026 | Mar 31, 2026 | -1.16 | -1.24 | -0.08 | -6.90% |
| Mar 31, 2026 | Dec 31, 2025 | -1.42 | -1.45 | -0.03 | -2.11% |
| Nov 14, 2025 | Sep 30, 2025 | -1.04 | -0.99 | +0.05 | +4.81% |
| Aug 14, 2025 | Jun 30, 2025 | -1.21 | -0.96 | +0.25 | +20.66% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | Barclays | down | Overweight | Equal-Weight |
| Jul 21, 2026 | Barclays | init | — | Overweight |
| Nov 25, 2025 | Evercore ISI Group | init | — | Outperform |
| Nov 17, 2025 | Chardan Capital | main | Buy | Buy |
| Aug 18, 2025 | Guggenheim | init | — | Buy |
| Aug 15, 2025 | Chardan Capital | main | Buy | Buy |
About Forte Biosciences Inc
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortebiorx.com
News
Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update 
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences 
12 Health Care Stocks Moving In Monday's Intraday Session 
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June 
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover 
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket 
Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac Data - 12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on FBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RILEY ANTONY A | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 30, 2026 | 42,600 |
| WAGNER PAUL A | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 30, 2026 | 85,482 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 9.94% | 2,110,516 | 162.49M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 7.43% | 1,577,705 | 121.47M | Jun 29, 2026 |
| Fred Alger Management, LLC | 6.78% | 1,439,697 | 110.84M | Jun 29, 2026 |
| Jupiter Topco LLC | 6.47% | 1,373,060 | 105.71M | Jun 29, 2026 |
| Blackrock Inc. | 5.76% | 1,222,862 | 94.15M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.40% | 1,145,391 | 88.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 5.90% | 1,251,500 | 96.35M | Apr 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 4.36% | 924,891 | 71.21M | Jul 30, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 3.92% | 832,100 | 64.06M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 622,927 | 47.96M | Jun 29, 2026 |
| ALGER FUNDS-Alger Small Cap Focus Fund | 2.34% | 496,062 | 38.19M | Apr 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 457,916 | 35.25M | Jun 29, 2026 |